Enanta Pharmaceuticals reported fiscal third quarter results ending June 30, 2026. Revenue was $14.4 million, down from $18.3 million in the prior year period due to lower AbbVie HCV sales. The company incurred a net loss of $19.5 million, or $0.67 per diluted share, compared to a $18.3 million loss previously. R&D expenses decreased to $22.1 million from $27.2 million as RSV trial costs declined. Cash and marketable securities totaled $211.5 million, providing a runway into fiscal 2029. Clinically, dosing began in the Phase 2b LOTUS pediatric RSV trial with topline data expected in 2027. The registrational RESOLVE adult RSV trial is on track for Q4 2026 initiation. Topline data from the Phase 1 EDP-978 urticaria trial and an IND filing for EPS-3903 are also targeted for late 2026. Enanta Pharmaceuticals, Inc. operates in the biotechnology industry, developing small molecule drugs for viral infections and immunological diseases.
